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1. Introduction 
Momordica charantia (MC) L. belongs to a short-fruited group of the Cucurbitaceae family 
and has been widely cultivated as a vegetable crop in many tropical and subtropical 
countries. The fruit, vines, leaves and roots of this plant have been used as a traditional 
medicine for the treatment of toothaches, diarrhea, furuncle, and diabetes [1-3]. Its fruit, 
referred to as kugua in the Chinese language, Mara Kee Nok in Thai and bitter melon in 
English, has been used in Chinese, Indian and Thai Cooking. Bitter melon, also known as 
bitter gourd, is cylindrical shaped and 4 to 12 inches in length and 1 and a half to 3 inches in 
diameter and contains large seeds inside. It tastes very bitter and is considered a blood 
purifier. It can be cut into rings and deep-fried for a snack. It is also often stir fried with 
meat, shrimp or fish. 
In view of the popularity of bitter melon in the Asian tropics and the fact that the results of 
using bitter melon as a remedy for diabetes has yielded conflicting results [2,4,5], more 
research needs to be done on its hypoglycemic activity. In addition, several compounds 
from bitter melon have shown interesting pharmacological activities, including antitumor, 
immunotoxic and anti-HIV properties, which merit further research, and may have strong 
potential in the development of future medicines [2,6-9]. Although different types of 
synthetic drugs are available for the treatment of chronic diseases, such as diabetes and 
cancer, the synthetic agents in use can produce serious side effects and toxicity. Hence there 
is a demand for safer and more effective agents. In many parts of the world, an Ayurvedic 
(traditional Indian) approach has been used for the treatment of a number of diseases, 
including diabetes and cancer and therein exists a hidden wealth of potential for useful 
natural products in the control of diseases. The World Health Organization (WHO) has 
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recommended that this area warrants further evaluation that might reveal effective dietary 
adjuncts, either for the treatment or prevention of specific diseases [10]. With traditional use 
supported by modern scientific evidence of the beneficial function of MC, it is one of the 
most promising plants for drug development. However, its phytochemicals and mechanism 
of action are poorly understood. Extensive research has studied the isolation of several 
classes of active components, including cucurbitane-type triterpenoids and the potential 
biological and pharmacological activities of natural products in MC [7,11]. The aim of this 
chapter is to review the cucurbitane type triterpenoids, particularly kuguacin J, in MC with 
the goal of encouraging future studies. 
1.1. Geographic distribution and monograph 
MC is an herbaceous, tendril-bearing vine growing up to 5 m in length. It bears simple, 
alternate leaves, with 3-7 deeply separated lobes. Each plant bears separate yellow male and 
female flowers [12]. Fruit 2.5-25 cm long, oblong, pendulous, fusiform, usually pointed or 
beaked, ribbed and bearing numerous triangular tubercles, 3 valves are present at the apex 
when mature. MC are perennial climbers cultivated throughout India and in Southern China 
and is now found naturalized in almost all tropical and subtropical regions. It is an important 
vegetable in India, Sri Lanka, Vietnam, Thailand, Malaysia, the Philippines and Southern 
China. It is also cultivated on a small scale in tropical America. MC is grown mainly for the 
production of immature fruit, although the young leaves are edible as a vegetable [3]. The 
young fruit is emerald green, but turns to orange-yellow when ripe. At maturity, the fruit 
splits into irregular valves that curl backwards and release numerous brown or white seeds 
encased in scarlet arils (Figure 1). All parts of the plant, including the fruit, taste bitter. It has 
been used extensively in traditional medicine as a remedy for diabetes.   
 
Figure 1. Flowers, immature fruit and young leaves of Momordica charantia (MC) at a home garden in 
Chiang Mai, Thailand (the picture was taken in March, 2012). 
1.2. Pharmacological activities 
Previous investigations have shown that water extracts of the leaf and fruit of MC exhibited 
high antioxidant activity and that bitter melon fractions are rich in phenolics and have a 
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strong antioxidant activity [13]. The role of free radicals and active oxygen in treating 
chronic diseases including cancer, aging and atheroscerosis has been recognized [14]. 
Therefore, much attention has been focused on the use of antioxidants in protecting against 
the threat of damage of free radicals. The active fractions from the fruit of MC have been 
reported to have significant hypoglycemic and antidiabetic effects [1,5]. Its active 
compounds were reported to be saponins [15,16] and peptides [17,18]. Charantin, an 
antidiabetic compound, is a typical cucurbitane-type triterpenoid in MC and is a potential 
and promising substance for the treatment of diabetes [19]. A number of studies have 
reported the effects of MC unrelated to diabetes. MC has some interesting biological and 
pharmacological activities. Extracts of MC have been reported to possess antitumor activity, 
such as the inhibition of mouse spontaneous mammary tumourigenesis [20] and 
benzo(a)pyrene-induced mouse forestomach tumourigenesis [21]. Besides, antioxidant 
activities [22], the antiviral [9], antidiabetic and immunomodulating properties [23] of this 
plant have also been explored. 
1.3. Ethnomedical uses  
The fruit, leaves and roots of MC have been used in Ayurveda in the treatment of a number 
of diseases. They have been used as a bitter stomachic, a laxative and an anthelmintic [24]. 
The whole extract of the fruit is also advocated in the treatment of diseases of the spleen, 
liver, and in rheumatism and gout [25]. An active ingredient from this plant has been used 
in diabetes mellitus [6,11,26]. In KwaZulu-Natal, the Zulus drink a concoction of the root or 
leaf for the treatment of boils and take an infusion of the runner as a sedative for an irritable 
stomach [27]. It has also been reported that it has been used as a remedy for hypertension 
and is reported to have antidiabetic properties. The leaf is used by the Chagga as an earache 
remedy [28] and in tropical Africa, the leaf is used to treat roundworm [29]. In Uganda, an 
infusion of the leaf and roots is used as an abortifacient and ecbolic [28] and in Tanzania the 
fruit pulp is regarded as being poisonous to weevils, moths and ants and is used as a 
repellant [30]. In the Philippines, the leaves are often used for children’s coughs. It is used in 
the treatment of skin diseases, sterility in women, as a parasiticide, as an antipyretic, and as 
a purgative. MC is also known as the Ampalaya tree, which is a vegetable grown 
throughout the Phillipines [31] and Ampalaya tea is a bitter brew made from the fruit or 
leaves. Ayurveda knowledge has claimed that Amapalaya stimulates digestion, helping 
those with dyspepsia or constipation. The tea seems to help people with diabetes mellitus 
control the disease, and it may provide some antimalarial benefits. Ampalaya has been 
traditionally regarded by Asians, as well as Panamanians and Columbians, as being useful 
in the prevention and treatment of malaria. Laboratory studies have confirmed that various 
species of the bitter fruit have anti-malarial activity, although human studies have not yet 
been published. In the Philippines, the effect of MC capsule preparation on glycemic control 
in type 2 diabetes mellitus has been studied [32]. However, there was no significant effect on 
mean fasting blood sugar, total cholesterol, and weight or on serum creatinine, ALT, AST, 
sodium and potassium in 40 outpatients who received treatment at the Phillippine General 
Hospital.  
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1.4. Phytochemicals and cucurbitane triterpenoids 
Since the early 1960’s the constituents of bitter melon have been investigated and several 
classes of primary and secondary metabolites have been isolated from MC fruits, seeds and 
whole plants. It contains biologically active chemicals that include crude fat, crude protein, 
soluble dietary fiber, minerals, essential oil, flavonoids, phenolic acids, glycosides and 
triterpenes. The young fruit is a good source of vitamin C and vitamin A [33-35]. A steroid 
saponin called charantin has been isolated from the fruits and leaves. It also contains a 
polypeptide named gurmarin, which is similar to insulin in composition.  
Among the secondary metabolites of MC, cucurbitane-type triterpinoids are one of the main 
bioactive constituents. The terpenoids, referered to as isoprenoids, are a class of natural 
products and the related compounds have been formally derived from five-carbon isoprene 
units. Terpenoids of different sizes and composition are found in all classes of living things 
and are the largest groups of naturally occurring chemicals. This class has been subdivided 
according to the number of carbon atoms. The triterpenoids are terpenoids with a C30 
skeleton. These C30 constituents are isolated and characterized from various sources in 
nature, particularly in resins and may occur as either esters or glycosides [36,37]. More 
extensive backbone rearrangement of the protostane cation affords the curcubitane skeleton. 
The cucurbitacins are a typical group of cucurbitane-type triterpenoids found in plants and 
belong to the cucumber family (Cucurbitaceae). The natural cucurbitracins are well-known 
for their bitterness and toxicity [38]. The cucurbitane-type triterpenoids and their aglycones 
have shown some biological effects beneficial in treating diabetes and obesity, and possess 
anticancer, anti-HIV and antifeedant properties [7,39]. More than fifty cucurbitacins and 
cucurbitane glycosides from the fruits, seeds, leaves, vines and stems have been reported 
[40-48]. Recently, Chen et al (2008, 2009) isolated and structured elucidation of nineteen 
cucurbitacins named kuguacins A-E from the roots of MC [49] and kuguacins F-S [50] from 
the vines and leaves of MC. They claimed that some of them are artifacts formed during 
the extraction process. The kuguacin C and E showed moderate anti-HIV-1 activity with 
EC50 values of 8.45 and 25.62 g/ml. The kuguacins F-S exhibited weak anti-HIV activities 
in vitro.  
Recently, several triterpenoids from various plants have been reported to feature anti-
proliferative [51-53] and anti-invasive [54,55] bioactive components. More than 50 
triterpenoids have been isolated from bitter melon, but their biological activities have yet to 
be explored in detail. However, it has been shown that Cucurbitacin B (cucB), a triterpenoid 
from Cucurbitaceae vegetables also found in bitter melon seeds, has caused cell cycle arrest 
and apoptosis induction in human colon adenocarcinoma cancer cells [53]. Moreover, 2 
flavonoids and 4 phenolic acids, including rutin, naringin, gentistic acid, benzoic acid, o-
coumaric acid, and t-cinnamic acid, are present in bitter melon leaves [35]. Rutin, a flavonoid 
glycoside, has been reported to successfully show growth inhibition of leukemia and 
ovarian carcinomas, with anti-invasive effects on melanoma [35,56-58]. Triterpenoids and 
flavoniods included in bitter melon leaf extract (BMLE) might be promising components 
with critical roles against cancer cell progression, but the active compound(s) remain to be 
identified. 
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This review presents previously published and current information regarding a cucurbitane 
type triterpenoid, kuguacin J, and provides new insights into the underlying potential of the 
chemical isolation and biological activities of kuguacin J in MC. Molecular mechanisms of 
kuguacin J, as a promising anticancer agent, will be discussed in detail.  
1.5. Isolation and purification of kuguacin J from MC leaf 
Our previous study [59] has compared the effects of the ethanolic extracts from leaves, fruits 
and tendrils of MC on drug accumulation and P-gp activity in vitro. The leaf extract (BMLE) 
showed a concentration-dependent effect on P-gp-mediated vinblastine accumulation and 
effux in drug resistant KB-V1 cells, but had no effect in drug-sensitive KB-3-1 cells, which 
lack P-gp, while there was no change in drug accumulation and efflux in KB-V1 cells in the 
presence of the fruit and tendril extracts [59]. These firstly inspired us to further identify the 
active component(s) of BMLE, which modulate the function of P-gp and the multidrug-
resistant (MDR) phenotype in multidrug-resistant human cervical carcinoma KB-V1 cells 
using Bioassay-guided fractionation. 
In the next study [60], the ethanolic fraction, BMLE, was subsequently extracted with 
solvents increasing in polarity (i.e., ethanol, hexane, diethyl ether, chloroform and ethyl 
acetate). These extraction samples were tested for their abilities to modulate the function of 
P-gp in the multidrug-resistant human cervical carcinoma KB-V1 cells in comparison with 
wild type drug sensitive KB-3-1 cells. Among the extracts tested, the hexane and diethyl 
ether fractions had the most effective MDR reversing properties, and increased intracellular 
[3H]-vinblastine accumulation and decreased the [3H]-vinblastine efflux in KB-V1 cells. The 
percent yield of the diethyl ether fraction was higher than the hexane fraction. Moreover, in 
another of our studies, the growth inhibitory effects on LNCaP cells showed that the diethyl 
ether fraction (DEF) of BMLE displayed the strongest inhibitory effect on the cell growth 
[61]. So, we therefore purified the active component using the diethyl ether fraction as a 
principle material. Bioassay-guided fractionation led us to isolate a purified white crystal. 
The IR, NMR and MS data of the compound was compared with previous reports [62] and it 
was identified as kuguacin J (3,7,23-trihydroxycucurbita-5,24-dien-19-al), (Figure 2). We 
further characterized the anticancer properties of BMLE (in vitro and in vivo) and kuguacin J 
(in vitro) and these will be further discussed in the following sections. 
2. Bitter melon and cancer 
Cancer is a disease in which the cell presents itself with uncontrolled proliferative potential. 
The transition of normal cells towards the cancerous phenotype occurs at various stages 
[63]. Since these defects are mostly due to aberrant signaling cascades involving numerous 
molecular players, targeting them by chemopreventive agents at any stage could be a 
rationalized approach in achieving the control of cancer. 
Carcinogenesis is generally a complex and multi-step process in which distinct molecular 
and cellular alterations occur. In order to simplify the understanding of the different 
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possible options for chemoprevention and chemotherapy in cancer development and 
progression, the following stages have been described: (i) initiation, when cells are exposed to 
a carcinogenic agent, (ii) promotion, when abnormal cells persist and initiate a preneoplastic 
stage (iii) progression, final phase of the tumorigenesis, when  uncontrolled cell growth is 
resistant to anticancer drugs (Multidrug Resistance; MDR), and aggressiveness or metastasis 
occur. A cancer chemopreventive agent could be effective at any of the classically defined 
stages of carcinogenesis: initiation, promotion, and/or progression [64,65]. As discussed earlier, 
extracts of bitter melon have been reported to possess anti-tumor activity [20,21] and the 
following sections detail the signaling cascades that are targeted. 
 
Figure 2. Chemical structure of kuguacin J isolated from MC. 
2.1. Anticancer in vitro studies 
Prevention by the use of naturally occurring dietary substances is considered a practical 
approach in reducing the increasing incidence of cancer. The intervention of multi-stage 
carcinogenesis by modulating intracellular signaling pathways may provide the molecular 
basis of chemoprevention with a wide variety of dietary phytochemicals [66,67]. 
Anticancer activities of MC against numerous cancers have revealed that it contains active 
compounds that provide anticancer potential to inhibit cell growth and proliferation, as well 
as to induce apoptotic cell death in several cancer cell lines [68-71]. Our studies [60,61,72,73] 
found that kuguacin J, one of the active compounds contained in MC extracts, exerts 
anticancer properties in various experimental models, which will be discussed further in the 
following sections. 
2.1.1. Antiproliferative and antiapoptotic activities 
Generally, deregulation of cell growth and resistance to apoptosis are the major defects in 
uncontrolled cancer cell growth, hinting that development of approaches that induce cell 
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cycle arrest and apoptotic machineries in cancer cells could be effective measures against 
their proliferation. Recently, dietary phytochemicals are considered promising 
chemopreventive or chemotherapeutic agents [67,74]. Thus, the induction of cell cycle arrest 
or apoptosis using dietary chemopreventive compounds might be an excellent approach to 
inhibit the promotion and progression of carcinogenesis and to remove genetically 
deregulated, premalignant and malignant cells from the body. We have investigated the 
growth inhibitory effect of BMLE and kuguacin J on androgen-dependent and androgen-
independent prostate cancer models [61,72,73]. 
Our study [61] found that BMLE exerted significant growth inhibitory effects on LNCaP via 
the induction of G1 arrest and apoptosis cell death and the alteration of cyclin D1, PCNA, 
Bcl-2/Bax, caspase-3 and cleaved caspase-3 protein levels. The data prompted us to 
characterize the active compound(s) in the extract, which could be valuable in the 
prevention and intervention of cancers. It was found that kuguacin J exerted a marked 
decrease of LNCaP cell proliferation and viability, suggesting that kuguacin J is at least one 
of the active components in BMLE that plays a critical role in the growth inhibition of 
LNCaP. 
The treatment of androgen-sensitive (LNCaP) cells with kuguacin J resulted in a significant 
G1-phase arrest of cell cycle progression [61], which indicates that one of the mechanisms by 
which kuguacin J may act to inhibit the proliferation of cancer cells is the regulation of cell 
cycle progression. We next examined the effect of kuguacin J on cell cycle regulatory 
molecules operative in the G1 phase of the cell cycle. The reduction of cyclinD1, cyclinE, 
Cdk2 and Cdk4 in LNCaP cells by kuguacin J suggests the disruption of the uncontrolled 
cell cycle progression of these cells and that the kuguacin J-induced G1 arrest is mediated 
through the up-regulation of p21 and p27 proteins, which enhances the formation of 
heterotrimeric complexes with the G1-S Cdks and cyclins, thereby inhibiting their activity. 
Additionally, kuguacin J also dramatically suppressed the expression of a proliferation 
marker, PCNA, which is expressed late in the G1 phase and early in the S phase [75]. The 
inhibition of cell proliferation or the induction of cell death in LNCaP by kuguacin J might 
be associated with the G1 arrest machinery. 
G1-phase arrest of cell cycle progression provides an opportunity for cells to either undergo 
repair mechanisms or follow the apoptotic pathway. Apoptosis plays a crucial role in that it 
functions as an essential mechanism of tissue homeostasis, eliminating the mutated 
neoplastic and hyperproliferating neoplastic cells from the system. Acquired resistance 
toward apoptosis is a hallmark of most, and perhaps all, types of cancer. Cancer cells 
become resistant to apoptosis and do not respond to the cytotoxic effects of the 
chemotherapeutic agents [76]. Therefore induction of apoptosis is considered a protective 
mechanism against cancer progression. We thus determined the effect of kuguacin J on the 
induction of apoptosis in LNCaP cells [61]. Kuguacin J treatment caused significant 
induction of apoptosis. Hence, kuguacin J seems to be a potent chemotherapeutic agent for 
prostate cancer inhibition. Moreover, kuguacin J treatment reduced the protein level of 
surviving, which might be associated with kuguacin J-induced cell cycle arrest and 
apoptosis in LNCaP. Kuguacin J treatment could alter the protein levels of key members of 
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the Bcl-2 family in a manner that favors an increase in the ratio of Bax/Bcl-2 and Bad/Bcl-xL 
and increases the activation of caspase-3 and cleavage of PARP. This may represent the 
mechanism by which cancer cells are susceptibility to kuguacin J mediated apoptosis.  
LNCaP is an androgen-dependent, androgen receptor (AR)-positive prostate cancer cell line. 
AR is known to play a critical role in the development and progression of prostate cancer 
[77]. The ability of AR to cross-talk with several growth factor signaling cascades toward the 
regulation of cell cycle, apoptosis, and differentiation outcomes in prostate cancer cells has 
been reported [77]. Inhibition of AR activity could be the major therapeutic goal to delay 
prostate cancer progression. Kuguacin J decreased the expression of AR followed by the 
reduction of the protein level of PSA [61], which is one major AR-dependent target gene. 
The diminishment of PSA represents the effective inhibition of AR activity by kuguacin J 
treatments. The decrease of AR might be involved in the kuguacin J-caused growth 
inhibition of LNCaP through the induction of G1 arrest and apoptosis. 
The tumor suppressor p53 protein is a regulator of genotoxic stress that plays an important 
role in DNA damage response, DNA repair, cell cycle regulation, and in triggering 
apoptosis after cell injury [78]. Induction of apoptosis is considered to be central to the 
tumor-suppressive function of p53 [79]. Kuguacin J-treated LNCaP cells markedly increased 
the expression of the p53 protein [61]. We further investigated whether kuguacin J-induced 
cell cycle arrest and apoptosis of LNCaP cells are p53-dependent using p53 RNA 
interference. We found that kuguacin J induced p53-mediated partly cell cycle arrest, and 
mainly apoptosis, which led to the inhibition of cell growth and may be related to the 
activation of p53 signaling pathway [61].  
Treatment of androgen-independent prostate cancer cells (PC3) with kuguacin J caused a 
significant G1-phase arrest along with a reduction of survivin, cyclinD1, cyclinE, Cdk2 and 
Cdk4 [73]. Kuguacin J also dramatically suppressed the expression of a proliferation marker, 
PCNA, that is expressed in both late G1 phase and early S phase [61,73] . 
Kuguacin J appears to inhibit the growth of the androgen-dependent LNCaP cells to a 
greater degree compared to the androgen-independent PC3 cell line [61,73]. A number of 
differences between PC3 and LNCaP cells may account for this difference in sensitivity. PC3 
is a more aggressively growing cell line and is null for both p53 and the AR. LNCaP is a 
much less aggressive cell line and possesses wild-type p53 and an AR, which although 
mutated, is responsive to androgen. Our study revealed that kuguacin J markedly decreased 
AR expression and induced p53 levels in LNCaP cells. We also found that p53 played a 
critical role in the kuguacin J-mediated induction of apoptosis by LNCaP cells. The data 
could explain the lower induction of apoptosis in PC3 cells compared to LNCaP. The 
induction of G1 arrest by kuguacin J, however, was similar in AR-dependent LNCaP cells 
and AR-independent PC3 cells, suggesting that the AR might not be a critical component in 
mediating the growth-arresting properties of kuguacin J. 
The sensitivity of the human normal prostatic epithelial cell line PNT1A to the cytotoxic 
effects of kuguacin J was much lower than that of the prostate cancer cell lines (LNCaP and 
PC3) [61]. Thus, kuguacin J could be an effective chemopreventive and chemotherapeutic 
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agent against prostate cancer, which might have no or a low side effect on normal cells and 
tissues. 
Our studies [61,73] provide the evidence that shows the significant inhibitory effects on 
carcinogenic progression of LNCaP and PC3 cells via inhibition of cell growth and 
proliferation by kuguacin J. Thus, kuguacin J is able to induce apoptosis/cell cycle arrest in 
pre-initiated/initiated tumor cells, while in more advanced tumors kuguacin J is still able to 
induce apoptosis/cell cycle arrest. Taken together, kuguacin J might be a promising 
candidate as a new chemopreventive agent for both androgen-dependent and androgen-
independent prostate cancer and could be developed as an alternative treatment option in 
cancer therapy. The in vivo study and growth inhibitory effects of kuguacin J on other 
cancers has to be further investigated. 
Because kuguacin J is a purified compound from BMLE, the differences of the anti-tumor 
effects between kuguacin J and BMLE were investigated. The growth inhibition effects of 
kuguacin J on LNCaP are similar to BMLE with the phenomena of cell cycle arrest and 
apoptosis induction and alteration of the expression of cell cycle- and apoptosis-regulators. 
However, kuguacin J is included as only 1.6% of the BMLE, and the effective concentration 
to inhibit cancer cell growth of kuguacin J was 10 times lower than that of BMLE [60,61,73]. 
Therefore, BMLE may include other compounds, which also have anti-tumor function 
towards LNCaP cells.  
2.1.2. Multidrug resistance reversing properties via modulation of P-glycoprotein function 
The development and strategic use of anticancer drugs has become one of the most 
important ways of controlling malignant diseases. However, the emergence of drug 
resistance has made many of the currently available chemotherapeutic agents ineffective. 
Efforts to reverse the drug resistance of tumor cells have been largely unsuccessful [80]. In 
recent years, considerable research has been directed toward understanding the underlying 
mechanisms that confer drug resistance. Many studies using tumor cell lines as model 
systems have demonstrated that the exposure of cells to one drug often results in cross-
resistance to many other structurally, chemically, and functionally distinct agents. This 
phenomenon is broadly known as the MDR phenotype [81-84]. The mechanism of MDR has 
now shown that some of the ATP-binding cassette (ABC) transporter proteins, especially 
ABCB1, or as it is more commonly referred to in literature, P-glycoprotein (P-gp), which is 
normally expressed in tumors derived from epithelial tissues including cancers of the 
kidney, liver, colon, and brain, has been associated with the intrinsic drug resistance of these 
cancers [85]. Some other tumors (for example breast, ovarian and small cell lung cancers) 
exhibit generally low levels of P-gp expression at diagnosis. However, the P-gp expression 
can be induced during the course of treatment, causing the cancer to become resistant to 
anticancer drugs [85]. At present, due in part to the disappointing results associated with the 
many side effects of P-gp modulators that have been used in clinical trials, current research 
efforts have been directed towards the identification of novel compounds with an attention 
toward dietary natural products or dietary herbs. The advantage is that these dietary herbs 
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exhibit little or virtually no side effects and do not further increase the patient’s medication 
burden. 
Our study investigated the effects of bitter melon extracts from leaves, fruits and tendrils on 
drug accumulation and P-gp activity in vitro [59]. We found that the leaf extract showed the 
greatest efficacy on P-gp-mediated vinblastine accumulation and effux in drug resistant KB-
V1 cells, but had no effect in drug-sensitive KB-3-1 cells, which lack P-gp. There was no 
change in drug accumulation and effux in KB-V1 cells in the presence of fruit and tendril 
extracts. The protein expression level of P-gp in KB-V1 cells was not altered by BMLE. 
Therefore, BMLE possibly modulates intracellular drug levels by inhibiting P-gp activity. 
We next identified the active component(s) in BMLE that act to modulate the function of P-
gp and the MDR phenotype in multidrug-resistant human cervical carcinoma using 
Bioassay-guided fractionation and led us to isolate a purified white crystal that was further 
identified as kuguacin J [60]. 
Kuguacin J increased the sensitivity of KB-V1 cells to vinblastine and paclitaxel, but did not 
have this effect on KB-3-1 cells [60]. Moreover, the treatment of KB-V1 and KB-3-1 cells with 
kuguacin J yielded a marked increase in C-AM and Rh123 accumulation in a concentration-
dependent manner in KB-V1 cells, but had no effect on KB-3-1 cells. C-AM and Rh123 are 
known to be good substrates for P-gp, indicating that kuguacin J modulates intracellular 
drug levels by inhibiting P-gp activity. The inhibitory effect of kuguacin J on P-gp function 
by [3H]-vinblastine transportation assays showed that kuguacin J also increased [3H]-
vinblastine accumulation in KB-V1 cells and decreased [3H]-vinblastine efflux from KB-V1 
cells. As our previous study showed, P-gp expression in KB-V1 cells was not affected by 
treating the cells with BMLE [59]. Our data suggests that kuguacin J inhibits P-gp activity, 
but does not inhibit its expression.  
The photoaffinity labeled transport substrate of P-gp, [125I]-IAAP, has been used extensively 
to study the interaction of the modulators at the substrate-binding site of P-gp [86]. It is also 
known that P-gp can be specifically labeled with [125I]-IAAP, and the drug-substrates of P-gp 
can inhibit the photocrosslinking of [125I]-IAAP to P-gp [87]. Kuguacin J inhibited the 
photocrosslinking of [125I]-IAAP to P-gp in a concentration-dependent manner. This is direct 
evidence that kuguacin J interacts with the substrate-binding site of P-gp. We further 
verified the interaction of kuguacin J with P-gp using an ATPase assay, which is another 
useful assay in the study of the interaction of transport-substrates with P-gp, as ATP 
hydrolysis is coupled with the transport function of this transporter [88]. Although 
kuguacin J had a negligible effect on the basal ATPase activity of P-gp, a low concentration 
of kuguacin J slightly stimulated P-gp-mediated ATP hydrolysis. This finding also implies 
that kuguacin J interacts with the substrate-binding site of P-gp. We next investigated the 
effect of kuguacin-J on verapamil-stimulated ATPase activity to further characterize the 
nature of the interactions of kuguacin J. Kuguacin J indeed inhibited the verapamil-
stimulated ATPase activity of P-gp. Furthermore, the kinetic analyses clearly showed that 
kuguacin J competes with verapamil for the substrate-binding site of P-gp. Taken together, 
the biochemical data suggest that kuguacin J inhibits the transport function of P-gp by 
interacting with the substrate-binding site of P-gp where verapamil also binds.  
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These results demonstrate that kuguacin J, an active compound isolated from BMLE, is an 
effective inhibitor of P-gp activity, and could be a candidate molecule for treating cancers 
exhibiting P-gp-mediated MDR. Investigations in animal experiments to determine whether 
kuguacin J has potential as an effective chemosensitizer that could be used in combination 
with conventional chemotherapy, needs to be explored. 
2.1.3. Modulation potential on cancer cell metastasis 
Metastasis, the spreading of malignant cells from the primary site to form a tumor mass at 
distant organs of the body, is the major cause of death in cancer patients. One of the critical 
characteristics of a metastatic cell is its invasion or ability to penetrate and invade the 
extracellular matrix and surrounding tissue. Invasion itself is a multistep process, requiring 
the coordination of various events, including the alteration of cell adhesion, promotion of 
cell migration, and degradation of the extracellular matrix barrier. Specifically, metastatic 
cells adhere to the basement membrane, secrete matrix-degrading enzymes such as matrix 
metalloproteinases (MMPs) to degrade the extracellular matrix barrier, and migrate from its 
original site. Therefore, the inhibition of these steps might be an effective approach in the 
prevention of cancer metastasis. The agents used in cancer metastasis therapy have been 
cytotoxic, with serious side effects that can diminish the quality of life of the cancer patients 
[89]. Recently, many efforts have therefore been made to search for non- or low-cytotoxic 
agents, which can reduce the spread of malignant tumors. One focus is to target cell 
invasion using substances found in medicinal plants [90,91]. 
We have provided clear evidence that BMLE can exert inhibitory potential against the 
metastatic properties of PLS10 cells in vitro [72]. Our results pointed to the beneficial effects 
at non-toxic levels. BMLE might thus afford an advantageous anti-cancer progression agent 
especially for tumor metastasis therapy. Non-cytotoxic BMLE treatment dramatically 
reduced migration and invasion properties and reduced, not only secretion, but also 
expression of MMP-2 and MMP-9 in androgen-independent rat prostate cancer cells. 
Additionally, uPA, which is an upstream enzyme of MMPs also implicated in tumor cell 
invasion, survival, and metastasis [92,93], was similarly reduced by BMLE treatment. Since 
TIMPs have the ability to form tight 1:1 complexes with the active MMP enzymes, changes 
in TIMP levels directly affect MMP activity [94,95]. BMLE treatment induced the expression 
of TIMP-2 that may be involved in the inhibition of tumor cell invasion. In addition, BMLE 
slightly reduced the proteolytic activity of collagenase type IV. Therefore, BMLE might 
mainly reduce the activity of MMPs by suppression of u-PA and induction of TIMP-2, and 
also may partially inhibit MMP activity through direct action. 
The exact nature of the active components of BMLE, which exerts anti-invasion effects, now 
needs to be explored along with further elucidation of the underlying molecular 
mechanisms. Kuguacin J, which already has been investigated for its effects to inhibit P-gp 
function and reverse MDR in cervical carcinoma [60] and to induce G1 arrest and apoptosis 
in human prostate cancer cell lines [61,73], could be a candidate for a purified compound 
with inhibitory activities against cancer cell invasion and metastasis. 
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Our study showed that non-cytotoxic levels of kuguacin J dramatically reduced the 
migration and invasion of androgen-independent human prostate cancer PC3 cells [73]. 
Kuguacin J treatment reduced the secretion of active MMP-2, but did not reduce mRNA 
expression. Importantly, kuguacin J treatment also reduced the expression of MT1-MMP. 
Besides, kuguacin J inhibited the secretion of active MMP-9 and uPA. MMP-9 expression 
also appeared to be reduced by kuguacin J, but the reduction was not significant. The 
activity of purified collagenase type IV was not directly modulated by kuguacin J, indicating 
that kuguacin J-mediated the inhibition of the PC3 MMP enzymes, but was not affected by 
the direct inhibition of their collagenase activities. 
BMLE and kuguacin J exert inhibitory effects in vitro on the progression of androgen-
independent rat and human prostate cancer cells, respectively, by suppressing cancer cell 
invasion and metastasis [72,73]. These provide a basis for the use of BMLE as a dietary 
supplement and kuguacin J as a broader antineoplastic agent for cancer progression. Further 
studies are underway to explore the molecular mechanisms of the action of kuguacin J and 
to determine its properties in vivo. 
2.2. Anticancer in vivo studies 
Kuguacin J has only been recently isolated [62], thus the chemopreventive effects of 
kuguacin J on cancer or the study of carcinogenesis in vivo have not been elucidated yet. An 
important limitation is that the yield of kuguacin J obtained after purification was not 
enough to perform in vivo experiments. On the other hand, bitter melon extract (BME), from 
which kuguacin J was purified, was reported to have anticancer effects in in vivo studies. 
The bitter melon seed or fruit extracts were shown to have anticancer activities in a rat 
colonic aberrant crypt foci model [96] and a mouse mammary tumor model [20]. Extracts of 
bitter melon fruits were reported to inhibit tumor formation of lymphoma cells (L1210 and 
P388) with intraperitoneal injections of BME inhibited tumor formation in CBA/H mice [8]. 
BME also inhibited aberrant crypt foci, which is known as preneoplastic lesion, in the rat 
colon [97]. In addition, seed oil from bitter melon was reported to inhibit aberrant crypt foci 
and carcinogenesis induced by azoxymethane in the rat colon through an elevation of 
peroxisome proliferator-activated receptor gamma expression and an alteration of lipid 
composition [98]. 
Other purified materials from BME were also reported to inhibit cancer and/or 
carcinogenesis. Momordica protein of 30 kDa (MAP30) from MC was reported to inhibit 
breast cancer in the tumor xenograft model. The treatment of human breast cancer-bearing 
SCID mice with MAP30 resulted in significant increases in survival, with 20–25% of the mice 
remaining tumor free for 96 days [99]. Administration of MCP30 decreased PC3 human 
prostate cancer cell growth by the induction of apoptosis in nude mice [71]. Recent studies 
further indicate that the chemical modification and reduction of ribosome-inactivating 
protein in BME, significantly reduced its in vivo immunogenicity, but retained its anti-
proliferative activity as measured by DNA fragmentation and caspase-3 activation [100]. 
Cucurbitane-type triterpenoids, charantosides, from a methanol extract of the fruits of MC 
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also inhibited mouse skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene 
(DMBA) or peroxynitrite plus 12-O-tetradecanoylphorbol-13-acetate (TPA) [45] α-ESA in 
bitter melon seed oil suppressing the growth of DLD-1 human colon cancer cells by 
apoptosis induction via lipid peroxidation [101]. α-ESA, which is converted to conjugated 
linoleic acid in vivo, had a stronger suppressive effect than the conjugated linoleic acid on 
tumor cell growth. 
We also have reported the anti cancer abilities of BMLE in vivo [72,73]. Dietary BMLE 
treatment tended to reduce lung weight and the number of lung metastatic tumors in a 
model in which intravenous inoculation of androgen-independent rat prostate cancer cells 
was injected into nude mice, resulting in a 100% incidence of lung metastasis [72]. Treatment 
of BMLE significantly reduced the percentage of the tumor area in the lungs in a dose-
response manner.  
In another study, while kuguacin J inhibited the migration and invasion of PC3 cells in vitro, 
dietary BMLE did not reduce metastasis to the lymph node but significantly reduced the 
growth of PC3 xenografts [73]. One reason why the differences in the incidence of lymph 
node metastasis between the control and the BMLE-diet fed animals could not be 
determined is that the PC3 xenograph model had a very low incidence of metastasis. Taking 
all the mice together, PC3 cells metastasized to the lymph node with an incidence of only 
3/20, 15%, while metastasis to other organs was not detected. 
Our in vitro data presented that the mechanism of the anticancer effects of kuguacin J were 
similar to BMLE in androgen-dependent and -independent prostate cancer via cell cycle 
arrest, apoptosis and invasion [61,72,73], suggesting that the possibility of in vivo anticancer 
effects of kuguacin J might be similar to BMLE. Therefore, further work using suitable in 
vivo models will be necessary to fully understand the in vivo activity of kuguacin J. 
With respect to in vivo toxicity, MC was shown to be safe with no signs of nephrotoxicity 
and hepatotoxicity without any adverse influence on food intake, growth organ weights and 
hematological parameters in experimental animals when ingested in low doses up to a 
period of 2 months [4,102]. The relatively low toxicity of all parts of this plant has also been 
reported when ingested, while toxicity and even death in laboratory animals has only been 
reported when the extracts were administered intravenously or by intraperitoneal injection 
in high doses [103]. MC has shown abortifacient activity traditionally, as well as 
experimentally [3,7]. The fruit and seeds demonstrated greater toxicity than the leaf or aerial 
parts of the plant. The documented adverse effects of MC are hypoglycemic coma and 
convulsions in children, reduced fertility in mice, a favism-like syndrome, increases in 
gamma-glutamyltransferase and alkaline phosphatase levels in animals, as well as 
headaches [3]. 
3. Conclusion  
A current strategy for the evaluation of anticancer phytochemicals is based in part on: (1) 
cell cycle and apoptosis regulation; (2) anti-oxidative stress and anti-inflammatory activities; 
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(3) drug resistance of cancer cells; and (4) specific molecular targets targeting carcinogenesis 
and metastasis. In our studies, BMLE and one of the tritepenoids included in BMLE, 
kuguacin J, have shown that they possess potent anticancer capabilities to induce 
apoptosis/cell cycle arrest in pre-initiated/initiated tumor cells, while in more advanced 
tumors, these compounds could block resistance to anticancer drugs, tumor progression and 
metastasis (Figure 3). These findings provide evidence of the anticancer effects of BMLE and 
kuguacin J (as summarized in Figure 3) and suggest the strong possibility that these natural 
products can be developed for cancer chemoprevention and chemotherapy.  
 
Figure 3. Summary of reported anticancer effects of bitter melon leaf extract and kuguacin J [59-
61,72,73]. 
The critical points to be investigated in future experiments include the fact that Kuguacin J 
accounts for only approximately 1.6% of BMLE [61]. BMLE is known to include several 
triterpenoids and flavoniods. Recently various triterpenoids have shown promising effects 
when applied as anticancer agents [104,105]. Cucurbitacin B (cucB), a triterpenoid from 
Cucurbitaceae vegetables also found in bitter melon seeds, caused cell cycle arrest and 
apoptosis induction in human colon adenocarcinoma cancer cells [53]. Additionally, Rutin, a 
flavonoid present in bitter melon leaves, has been reported to display growth inhibition of 
leukemia and ovarian carcinoma cells, with anti-invasive effects on melanoma cells [35,56-
58]. Therefore, BMLE may include other bioactive compounds apart from kuguacin J, which 
exert anti-tumor effects, although human studies have not yet been published. Thus, a 
characterization of other active components present in BMLE needs to be further elucidated. 
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In addition, the absorption and metabolism of the bioactive compounds after consumption 
remains to be investigated as to whether a test tube study can be applicable to people. 
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